Literature DB >> 17529883

Protein binding of flucloxacillin in neonates.

Joyce Pullen1, Leo M L Stolk, Pieter L J Degraeuwe, Frank H van Tiel, Cees Neef, Luc J I Zimmermann.   

Abstract

The isoxazolyl penicillins, including flucloxacillin, have the highest levels of plasma protein binding among the semisynthetic penicillins. Because only the free fraction of the penicillin is pharmacologically active, it would be useful to measure both protein-bound and free flucloxacillin to determine its protein binding. Until now, flucloxacillin protein binding in newborn infants has been investigated in only two studies with relatively small populations. In the present study, flucloxacillin protein binding was investigated in 56 (preterm) infants aged 3 to 87 days (gestational age, 25-41 weeks). Surplus plasma samples from routine gentamicin assays of each infant were collected and combined to obtain a sufficiently large sample for analysis. Free flucloxacillin was separated from protein-bound flucloxacillin using ultrafiltration. Reversed-phase high-performance liquid chromatography with ultraviolet detection was used to measure free flucloxacillin concentrations in ultrafiltrate and total flucloxacillin concentrations in pooled plasma. Flucloxacillin protein binding was 74.5% +/- 13.1% (mean +/- standard deviation) with a high variability among the infants (34.3% to 89.7%). High Pearson correlations were found between protein binding and the covariates-plasma albumin concentration (r = 0.804, P < 0.001, n = 18) and plasma creatinine concentration (r = -0.601, P < 0.001, n = 45). Statistically significant but less striking correlations were found between protein binding and gestational age, postconceptional age, body weight, and triglyceride concentration. Because of the high variability of protein binding among infants, it is difficult to devise a flucloxacillin dosage regimen effective for all infants. Individualized dosing, based on free flucloxacillin concentrations, might help to optimize treatment of late-onset neonatal sepsis, but practical obstacles will probably prevent analysis of free flucloxacillin concentrations in newborn infants on a routine basis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17529883     DOI: 10.1097/FTD.0b013e318063e30f

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

Review 1.  The interplay between drugs and the kidney in premature neonates.

Authors:  Michiel F Schreuder; Ruud R G Bueters; Karel Allegaert
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

2.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

3.  Cefazolin plasma protein binding and its covariates in neonates.

Authors:  A Smits; A Kulo; R Verbesselt; G Naulaers; J de Hoon; P Vermeersch; K Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

4.  Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation.

Authors:  Min Kan; Hai-Yan Shi; Zhong-Guo Sui; Wei Zhao; Bing Han; Yue-E Wu; Qian Li; Zi-Xuan Guo; Xue Li; Guo-Xiang Hao; Yi Zheng; Le-Qun Su; Xin Huang
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

6.  Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?

Authors:  Gloria Wong; Scott Briscoe; Syamhanin Adnan; Brett McWhinney; Jacobus Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.